Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3866288 · 2 trials · 1 indication
PK: AUC From Time 0 to the Time of the Last Quantifiable Concentration of LY3866288
PK: Cmax of LY3866288
| Arm | Type | Description |
|---|---|---|
| Part A: [14C]-LY3866288 | EXPERIMENTAL | Single dose of \[¹⁴C\]-LY3866288 administered orally. |
| Part B: LY3866288 + [14C]-LY3866288 | EXPERIMENTAL | Single dose of LY3866288 administered orally followed by a single dose of \[¹⁴C\]-LY3866288 administered intravenously (IV). |
| LY3866288 Cohort 1 (High-Fat Meal) | EXPERIMENTAL | LY3866288 single and multiple capsules administered orally under fasted/fed conditions in cross-over manner within cohort |
| LY3866288 Cohort 2 (Low-Fat Meal) | EXPERIMENTAL | LY3866288 single and multiple capsules administered orally under fasted/fed conditions in cross-over manner within cohort |
| Name | Type | Description |
|---|---|---|
| [14C]-LY3866288 | DRUG | Administered orally. |
| LY3866288 | DRUG | Administered orally. |
Inclusion Criteria: * Male and female participants who are overtly healthy determined by medical history, physical examination, 12-lead ECGs, vital signs measurements, and clinical laboratory evaluations at screening and/or check-in by the investigator * Have Body mass index between 18.0 and 32.0 k...
LY3866288 is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development, studied in healthy participants. Two Phase 1 trials have been completed, with a total enrollment of 30 participants.
LY3866288 is being studied in healthy participants, meaning it is not yet being tested for a specific disease or condition. Its intended therapeutic use has not been established, as it is in early-stage clinical development.
LY3866288 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker symbol LLY.
LY3866288 is in Phase 1 clinical development. Two Phase 1 trials have been completed, both in healthy participants. It is an investigational drug and has not been approved by regulatory authorities.
LY3866288 has been studied in two completed Phase 1 trials: NCT06641037, a study in healthy participants, and NCT06644378, a study of [14C]-LY3866288 in healthy participants. Both trials were conducted in the United States.